Royalty Pharma PLC Schedule 13G passive stakes

Capital International Investors reports beneficial ownership of 8.8% of Royalty Pharma PLC's common stock as of March 31, 2026.

Capital International Investors has reported a 6.6% beneficial ownership stake in Royalty Pharma PLC, holding 28,512,128 shares of common stock.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 6.5% beneficial ownership stake in Royalty Pharma PLC's Class A Common Stock as of September 30, 2025.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 2.52% in Royalty Pharma PLC as of September 30, 2025.

General Atlantic and its affiliated entities have disclosed a beneficial ownership of 3.2% in Royalty Pharma plc, holding over 14.2 million Class A ordinary shares.

Capital International Investors has disclosed a 5.5% beneficial ownership stake in Royalty Pharma PLC, holding over 23 million common shares.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., reported increased beneficial ownership in Royalty Pharma plc, now holding 9.2% and 8.5% respectively.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, confirming their beneficial ownership of 9.1% of Royalty Pharma PLC's Class A Common Stock as of March 31, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, disclosing a beneficial ownership of 5.9% of Royalty Pharma PLC's Class A Common Stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing a significant beneficial ownership of 5.7% in Royalty Pharma PLC as of December 31, 2024.